This poses a challenge, as it can lead to dose-limiting toxicities or limited efficacy when targeting specific pathways or cell types.169,193,307,308 Taking FDA-approved IL-2 as an example, although it has shown the ability to induce tumor regression, its effectiveness in improving patients’ overall survival is limited. Here, IL2 is linked to neoplasm.